By John LovettUniversity of Arkansas System Division of AgricultureArkansas Agricultural Experiment StationFAYETTEVILLE, Ark. — An experimental ...

A new scale for grading ocular adverse events in oncology trials addresses ambiguities in CTCAE version 5 and includes dose modification recommendations. The scale, implemented in the I-SPY 2 trial, ...

Discovering effective drug combinations may now be easier thanks to a screening platform made public today by St. Jude ...

Immunome said on Monday its experimental drug met the main goal in a late-stage study for patients with a rare type of tumor, sending its shares up 25% in morning trade. The trial results set the ...

Gilead Sciences said on Monday its experimental HIV treatment was found to be statistically non-inferior to its top-selling ...

Sanofi drug faces FDA delay following a failed late-stage trial for multiple sclerosis, with regulatory guidance expected by Q1 2024.

Sanofi flagged a second delay to an FDA decision for its experimental multiple sclerosis drug and reported disappointing ...

Shares in argenx fell after the pharmaceutical company said it would stop late-stage trials for an experimental drug to treat thyroid eye disease due to lack of efficacy. In European afternoon trading ...

Shares of French pharmaceutical group Sanofi fell 4% on Monday after it flagged another delay to a U.S. regulatory decision ...

Dec 15 () - Shares of French pharmaceutical group Sanofi fell 4% on Monday after it flagged another delay to ​a U. regulatory ...

Sanofi shares slide after FDA delays review of its MS drug tolebrutinib and a late-stage trial fails to meet its main goal.

Immunome said on Monday its experimental drug met the main goal in a late-stage study for patients with a rare type of tumor.